Researchers published a study in Cellular & Molecular Biology Letters demonstrating that histone lactylation plays a critical role in ameliorating postmenopausal osteoporosis. The investigation, led by Chaoqing Huang and Yuan Wang, identified a specific molecular pathway through which this epigenetic modification promotes bone formation. By stabilizing the SMAD1 protein via an IGF2BP1-dependent mechanism, the process helps counteract the bone loss typically associated with menopause. The findings offer new insights into the epigenetic factors that influence the pathogenesis of osteoporosis.
The study focused on the interplay between histone modifications and N6-methyladenosine (m6A) methylation in the context of osteoporosis. Epigenetic changes are known to affect disease progression, and RNA and histone modifications have recently attracted significant scientific attention. The authors sought to clarify the specific role of histone lactylation in this process. They utilized an ovariectomy (OVX) mouse model to simulate postmenopausal conditions and conducted in vitro experiments using osteogenic-induced bone marrow mesenchymal stem cells (BMSCs).
Initial results indicated that levels of whole lactylation and H3K18 lactylation were decreased in the OVX-induced mice. Conversely, these levels were elevated in osteogenic BMSCs, suggesting a potential link between lactylation and bone formation. To test this relationship, the researchers inhibited H3K18 lactylation using oxamate. This inhibition promoted bone defects and suppressed the osteogenic differentiation of BMSCs. When they promoted H3K18 lactylation using Nala, the opposite effects were observed, with improved bone outcomes.
The investigation further revealed that H3K18 lactylation was enriched in the promoter region of the IGF2BP1 gene. This enrichment facilitated the transcription of IGF2BP1, linking the histone modification directly to the expression of this specific protein. The study found that overexpressing IGF2BP1 attenuated the bone defects induced by OVX. In contrast, knocking down IGF2BP1 inhibited osteogenesis, highlighting the protein’s importance in maintaining bone health.
At the molecular level, IGF2BP1 was shown to recognize the m6A methylation of SMAD1. This recognition enhanced the stability of the SMAD1 protein, preventing its degradation. The researchers demonstrated that overexpressing SMAD1 could reverse the inhibition of osteogenesis and bone defects caused by silencing IGF2BP1. This suggests that the stability of SMAD1 is a key downstream effect of the IGF2BP1 pathway in bone formation.
The study concludes that histone lactylation alleviates osteoporosis by promoting osteogenesis through the transcriptional regulation of IGF2BP1. IGF2BP1, in turn, recognizes the m6A methylation of SMAD1, thereby stabilizing it. This cascade of events provides a detailed mechanism for how epigenetic modifications can influence bone biology. The findings underscore the complexity of the molecular networks involved in postmenopausal osteoporosis.
While the study provides valuable insights into the molecular mechanisms of osteoporosis, it is important to note that the research was conducted in mouse models and cell cultures.
The publication of this research contributes to the growing body of knowledge on the role of epigenetics in bone diseases. The work by Huang and Wang represents a significant step forward in understanding the intricate relationship between histone modifications and bone health.
Subject of Research: Molecular mechanisms of histone lactylation in postmenopausal osteoporosis
Article Title: Histone lactylation ameliorates postmenopausal osteoporosis by IGF2BP1-dependent SMAD1 stabilization
Article References: Huang, C., & Wang, Y. (2026). Histone lactylation ameliorates postmenopausal osteoporosis by IGF2BP1-dependent SMAD1 stabilization. Cellular & Molecular Biology Letters. https://doi.org/10.1186/s11658-026-01006-7
Image Credits: AI Generated
DOI: 10.1186/s11658-026-01006-7
Keywords: osteoporosis, histone lactylation, epigenetics, SMAD1, IGF2BP1, bone biology, postmenopausal, m6A methylation, Histone, lactylation, ameliorates, IGF2BP1-dependent
News Source: Drew Townsend. (November 7, 2026). Histone lactylation boosts bone formation in postmenopausal osteoporosis. Scienmag.



